Epilepsy and Seizure Management for OPRA: Drug Selection by Seizure Type, the Valproate Warning and MCQs

Focal vs generalised seizures — the classification that drives drug choice

Focal (partial) seizures start in one area of the brain and may or may not impair awareness, sometimes evolving into a focal-to-bilateral tonic-clonic seizure. Generalised seizures involve both hemispheres from onset and include several distinct subtypes — tonic-clonic (the seizure most people picture), absence (brief lapses in awareness, previously called petit mal), myoclonic (brief muscle jerks), tonic and atonic. OPRA stems usually describe the seizure rather than naming the classification outright — a stem describing brief, repeated staring spells in a child is describing absence seizures, not simply 'epilepsy,' and the correct drug choice changes accordingly.

A reasoning framework, not a drug list

Real ASM selection depends on more than seizure type alone — the epilepsy syndrome, age, reproductive-risk factors, comorbidities, interactions and adverse-effect profile all matter, and treatment is individualised rather than read off a single fixed table. A more durable approach for OPRA is to work through the same five questions each time: (1) What seizure type is this — focal, absence, myoclonic, tonic-clonic, or more than one type together? (2) Does this need a narrow-spectrum or broad-spectrum drug? (3) Who is the patient — could they become pregnant, are they male and planning to father a child, what else is relevant about their age or comorbidities? (4) What else are they taking — hormonal contraception, warfarin, another ASM? (5) Is this an emergency — is this status epilepticus, where the priority is an immediate benzodiazepine rather than drug selection at all? Working through that sequence transfers to seizure-type combinations and patient scenarios a fixed drug list won't cover.

High-yield ASM selection by seizure type

• Focal seizures: levetiracetam or lamotrigine are commonly preferred options; carbamazepine remains an effective and widely used alternative.
• Generalised tonic-clonic seizures: sodium valproate is highly effective, but levetiracetam or lamotrigine are frequently preferred in anyone who could become pregnant, because of valproate's reproductive-risk profile (see below).
• Absence seizures: ethosuximide is a strong choice for PURE absence seizures — but it does not protect against generalised tonic-clonic seizures. Where absence and generalised tonic-clonic seizures coexist in the same patient, a broader-spectrum option such as sodium valproate is generally more appropriate than ethosuximide alone. Carbamazepine is avoided for absence seizures, as it can worsen them.
• Myoclonic seizures: sodium valproate or levetiracetam are typical choices. The transferable principle is that some ASMs can aggravate generalised epilepsies rather than treat them — but the mechanisms differ, and grouping them together is itself an exam trap. Carbamazepine and phenytoin are sodium-channel blockers, and that sodium-channel action is what can worsen absence and myoclonic seizures. Gabapentin works differently — it binds the α2δ subunit of voltage-gated calcium channels, not sodium channels — yet it can also aggravate certain generalised seizure types, which is why it is a poor choice in these epilepsies despite the different mechanism. Learn the two mechanisms separately and the clinical caution attached to each; a single 'narrow-spectrum drugs are all sodium-channel blockers' shortcut is wrong. One further trap sits in the opposite direction: lamotrigine is broad-spectrum, so it is tempting to reason that it must therefore be safe across all generalised seizure types. It is not — lamotrigine may aggravate myoclonic seizures in some patients, particularly in juvenile myoclonic epilepsy. Breadth of spectrum is not the same as suitability for every seizure type within it.
• A single ASM can be right for one seizure type and wrong for another — 'this drug treats epilepsy' is not the same clinical claim as 'this drug treats this patient's seizure type.'

The sodium valproate reproductive-risk warning

Sodium valproate carries one of the strongest reproductive-risk warnings of any commonly used medicine. Exposure in pregnancy is associated with a significantly increased risk of major congenital malformations (including neural tube defects) and neurodevelopmental disorders in the child, and Australian TGA guidance states that sodium valproate is contraindicated in pregnancy and should not be used in people of child-bearing potential unless alternative treatments are ineffective or not tolerated for their specific seizure type, with specific, documented counselling on contraception and pregnancy planning where it is used. Australia has also strengthened guidance on PATERNAL exposure: current Australian product information includes warnings about a possible increased risk of neurodevelopmental disorders in children fathered by men taking valproate in the months before conception, alongside the established maternal warnings — this is an important current Australian safety update that candidates working from older study material may miss. It's equally important not to overcorrect: unlike the United Kingdom, Australia has not introduced a blanket age-based restriction on valproate use (for example, a rule limiting use to over a certain age) — the TGA specifically reviewed the UK's approach and concluded there was insufficient evidence to justify equivalent restrictions here. A candidate who has studied UK-sourced material may incorrectly import the UK position; the Australian approach is individualised risk-benefit assessment, not a blanket restriction.

Practise this topic

Matching ASM to seizure type — and recognising when the most effective drug is still the wrong answer for a specific patient — is useful OPRA-style practice, because it's exactly the kind of multi-factor reasoning real prescribing decisions require. Practise more Therapeutics and Neurological Conditions OPRA questions with ClinicalStem's OPRA question bank.

Enzyme induction: don't memorise the interaction, recognise the mechanism

Carbamazepine, phenytoin, phenobarbitone (phenobarbital) and primidone are potent hepatic enzyme inducers. The mechanism is what's transferable: enzyme-inducing ASM → increased hepatic metabolism → reduced concentrations of other drugs cleared by the same pathways → reduced efficacy of those other drugs, most importantly hormonal contraceptives and warfarin. A woman on carbamazepine and a combined oral contraceptive is at real risk of contraceptive failure from the interaction alone, regardless of adherence to either medicine — a genuinely common, testable scenario rather than an edge case, and one where reasoning from the mechanism will get you to the right answer even for a drug pairing you haven't specifically memorised.

Lamotrigine's two-way interaction with hormonal contraception

The interaction between lamotrigine and combined hormonal contraception runs in both directions. Oestrogen-containing contraceptives induce lamotrigine's glucuronidation, substantially reducing lamotrigine concentrations and risking breakthrough seizures — while stopping the contraceptive (for example during the pill-free interval, or ceasing it altogether) can increase lamotrigine concentrations correspondingly, with a risk of dose-related adverse effects and toxicity. Sodium valproate has the opposite effect on lamotrigine — it inhibits lamotrigine's metabolism and meaningfully increases levels, which is why lamotrigine requires a much slower titration schedule when co-prescribed with valproate, specifically to reduce the risk of serious rash (including Stevens-Johnson syndrome).

Status epilepticus: the emergency principle

Convulsive status epilepticus should be treated as an emergency once a convulsive seizure reaches 5 minutes or more, or when recurrent seizures occur without recovery of consciousness between them. The threshold matters: and the exam principle worth fixing is simple: give an appropriate benzodiazepine promptly, according to the clinical setting and available route, rather than waiting or reaching first for a non-benzodiazepine option. In a hospital setting this is typically IV lorazepam (or IV diazepam if lorazepam isn't available); outside hospital — which is the setting a community pharmacist is actually likely to encounter — buccal midazolam or rectal diazepam are commonly used because IV access usually isn't available. If seizures continue despite an appropriate benzodiazepine, a second-line IV antiseizure medicine is given according to local protocol — phenytoin (or fosphenytoin), sodium valproate or levetiracetam are all used — escalating to general anaesthesia if seizures remain refractory. The exam-relevant point is the correct FIRST step and its urgency (a benzodiazepine given without delay, not an oral ASM and not immediately reaching for phenytoin), not memorising IV lorazepam as the universal answer regardless of setting.

Is sodium valproate ever used in people of childbearing potential?

It can be, but only when alternative ASMs suitable for the seizure type have failed or aren't tolerated, and with clear, documented counselling about the reproductive risks, contraception and pregnancy planning — it isn't an absolute contraindication outside pregnancy itself, but the threshold for using it in this population is deliberately high, and current use, not just current pregnancy status, is what's assessed.

Does valproate carry any risk for male patients?

Current Australian product information includes a warning about a possible increased risk of neurodevelopmental disorders in children fathered by men taking valproate in the months before conception, alongside the long-established maternal warnings. Existing recommendations for people who could become pregnant remain unchanged — this is an addition, not a replacement.

Does Australia restrict valproate use in the same way the UK does?

No — the UK has introduced stricter, age-based prescribing restrictions for valproate. The TGA reviewed this approach and concluded there was insufficient evidence to introduce equivalent blanket restrictions in Australia; the Australian approach remains individualised risk-benefit assessment rather than a fixed age cut-off. This is a genuine difference worth knowing if you've studied UK-sourced material.

Why does carbamazepine treat some seizure types but worsen others?

Carbamazepine's mechanism suits focal seizures but can paradoxically worsen absence and myoclonic seizures, which is why matching the drug to the specific seizure type — not just 'epilepsy' as a diagnosis — is essential.

Do all antiseizure medicines interact with hormonal contraception?

No — the interaction is specific to enzyme-inducing ASMs (carbamazepine, phenytoin, phenobarbitone, primidone, and to a lesser extent some others). Levetiracetam is not an enzyme inducer in the same way, though lamotrigine has its own distinct, bidirectional interaction with combined hormonal contraception via a different mechanism.

What is the first-line treatment for status epilepticus?

An appropriate benzodiazepine, given without delay — the specific agent and route depend on the setting (for example IV lorazepam in hospital, or buccal midazolam/rectal diazepam where IV access isn't available). If seizures continue, a second-line IV antiseizure medicine (phenytoin/fosphenytoin, valproate or levetiracetam) is used according to local protocol, escalating to general anaesthesia if seizures remain refractory.